TD Asset Management Inc Sells 8,030 Shares of Align Technology, Inc. $ALGN

TD Asset Management Inc trimmed its holdings in shares of Align Technology, Inc. (NASDAQ:ALGN) by 4.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 162,290 shares of the medical equipment provider’s stock after selling 8,030 shares during the quarter. TD Asset Management Inc owned 0.22% of Align Technology worth $30,726,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Envestnet Portfolio Solutions Inc. lifted its holdings in Align Technology by 4.5% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 2,372 shares of the medical equipment provider’s stock valued at $449,000 after buying an additional 102 shares in the last quarter. Sequoia Financial Advisors LLC lifted its holdings in Align Technology by 153.2% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 3,433 shares of the medical equipment provider’s stock valued at $650,000 after buying an additional 2,077 shares in the last quarter. M.E. Allison & CO. Inc. raised its stake in shares of Align Technology by 19.5% during the second quarter. M.E. Allison & CO. Inc. now owns 1,750 shares of the medical equipment provider’s stock valued at $331,000 after acquiring an additional 285 shares in the last quarter. CWM LLC raised its stake in shares of Align Technology by 43.7% during the second quarter. CWM LLC now owns 13,271 shares of the medical equipment provider’s stock valued at $2,513,000 after acquiring an additional 4,034 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its stake in shares of Align Technology by 16.3% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 12,971 shares of the medical equipment provider’s stock valued at $2,456,000 after acquiring an additional 1,817 shares in the last quarter. 88.43% of the stock is currently owned by institutional investors.

Align Technology Stock Up 1.1%

NASDAQ ALGN opened at $129.84 on Friday. The firm has a market cap of $9.41 billion, a PE ratio of 21.90, a price-to-earnings-growth ratio of 1.46 and a beta of 1.70. The company has a 50 day moving average price of $134.90 and a 200 day moving average price of $163.49. Align Technology, Inc. has a 52 week low of $122.00 and a 52 week high of $246.19.

Align Technology (NASDAQ:ALGN) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $2.49 EPS for the quarter, missing the consensus estimate of $2.57 by ($0.08). The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.06 billion. Align Technology had a return on equity of 13.36% and a net margin of 11.04%.The company’s revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.41 EPS. Align Technology has set its Q3 2025 guidance at EPS. On average, equities research analysts anticipate that Align Technology, Inc. will post 7.98 earnings per share for the current fiscal year.

Align Technology declared that its Board of Directors has authorized a share repurchase plan on Tuesday, August 5th that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the medical equipment provider to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

ALGN has been the subject of a number of research analyst reports. Weiss Ratings lowered Align Technology from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, October 8th. Morgan Stanley restated an “equal weight” rating and issued a $154.00 price objective (down from $249.00) on shares of Align Technology in a report on Thursday, July 31st. Mizuho reduced their price target on shares of Align Technology from $210.00 to $170.00 and set an “outperform” rating for the company in a report on Monday. UBS Group reduced their price target on shares of Align Technology from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Thursday. Finally, Evercore ISI reduced their price objective on shares of Align Technology from $170.00 to $160.00 and set an “outperform” rating for the company in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $182.67.

Insider Activity

In related news, CEO Joseph M. Hogan acquired 7,576 shares of the business’s stock in a transaction dated Friday, August 1st. The shares were purchased at an average price of $131.49 per share, for a total transaction of $996,168.24. Following the completion of the acquisition, the chief executive officer directly owned 184,945 shares in the company, valued at $24,318,418.05. The trade was a 4.27% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.66% of the stock is currently owned by company insiders.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.